NCT02924558

Brief Summary

The goal of this study is to evaluate the effects of replacing some refined starches and added sugars with a combination of egg protein and unsaturated fatty acids on markers of cardiometabolic health in men and women with hypertriglyceridemia.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2015

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2016

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

October 3, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 5, 2016

Completed
Last Updated

May 15, 2018

Status Verified

May 1, 2018

Enrollment Period

1 year

First QC Date

October 3, 2016

Last Update Submit

May 11, 2018

Conditions

Keywords

EggProteinUnsaturated fatty acidsTriglyceridesInsulin sensitivityLipid triad

Outcome Measures

Primary Outcomes (1)

  • Matsuda composite index of insulin sensitivity (MISI)

    Difference between treatments in percent change from baseline to end of treatment MISI calculated from glucose and insulin responses to the LMTT at Visit 2, Day 0 (baseline); Visit 6, Day 21 (end of treatment period I); and Visit 11, Day 21 (end of treatment period II)

    3 weeks

Secondary Outcomes (7)

  • Lipoprotein lipids

    3 weeks

  • Lipoprotein particle concentrations

    3 weeks

  • Apolipoprotein (Apo) B

    3 weeks

  • Homeostasis model assessment of insulin sensitivity (HOMA2-%S)

    3 weeks

  • LMTT disposition index

    3 weeks

  • +2 more secondary outcomes

Study Arms (2)

Egg protein/unsaturated fatty acid

EXPERIMENTAL

8% higher protein energy (from egg protein) and 8% higher fat energy (from unsaturated fatty acids); approximately 42/23/35% kcal from carbohydrate/protein/fat, respectively

Other: Egg protein/unsaturated fatty acid

Control

PLACEBO COMPARATOR

16% higher carbohydrate energy; approximately 58/15/27% kcal from carbohydrate/protein/fat, respectively

Other: Control

Interventions

Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control

Egg protein/unsaturated fatty acid
ControlOTHER

Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid

Control

Eligibility Criteria

Age21 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Fasting TG level 150-499 mg/dL
  • Body mass index (BMI) 25.0-39.9 kg/m2
  • Score of 7-10 on Vein Access Scale
  • Normally active and judged to be in general good health on basis of medical history and routine laboratory tests

You may not qualify if:

  • Fasting blood glucose ≥126 mg/dL or known type 1 or type 2 diabetes mellitus
  • Atherosclerotic cardiovascular disease
  • Recent history or current significant renal, pulmonary, hepatic, biliary, or gastrointestinal disease
  • Abnormal lab test results of clinical significance (e.g., creatinine ≥1.5 mg/dL and aspartate or alanine transaminase ≥1.5 times upper limit of normal)
  • History of cancer in previous 2 years
  • Uncontrolled hypertension
  • Recent unstable use of anti-hypertensive medication, thyroid hormone replacements, and/or medications known to substantially influence carbohydrate metabolism
  • Recent use of certain blood pressure medications (e.g., beta-adrenergic blockers and/or high-dose thiazide diuretics)
  • Recent use of lipid-altering drugs (e.g., statins, bile acid sequestrants, cholesterol absorption inhibitors, or fibrates)
  • Recent use of diabetes medication (e.g., alpha-glucosidase inhibitors, biguanides and biguanide combinations, bile acid sequestrants, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, meglitinides, and sulfonylureas and combination sulfonylureas)
  • Recent use of lipid-altering foods, herbs, or dietary supplements (e.g., niacin, sterol/stanol products, dietary fiber supplements, red rice yeast supplements)
  • Recent unstable use of herbs and dietary supplements that may influence carbohdyrate metabolism
  • Extreme dietary habits, dietary restrictions, or significant food allergies
  • Required energy intake \<2200 kcal/day or \>3400 kcal/day
  • Recent change in body weight of ±4.5 kg
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Maki KC, Palacios OM, Lindner E, Nieman KM, Bell M, Sorce J. Replacement of Refined Starches and Added Sugars with Egg Protein and Unsaturated Fats Increases Insulin Sensitivity and Lowers Triglycerides in Overweight or Obese Adults with Elevated Triglycerides. J Nutr. 2017 Jul;147(7):1267-1274. doi: 10.3945/jn.117.248641. Epub 2017 May 17.

MeSH Terms

Conditions

HypertriglyceridemiaInsulin Resistance

Interventions

Egg ProteinsFatty Acids, Unsaturated

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesHyperinsulinismGlucose Metabolism Disorders

Intervention Hierarchy (Ancestors)

ProteinsAmino Acids, Peptides, and ProteinsFatty AcidsLipids

Study Officials

  • Kevin C Maki, PhD

    Midwest Center for Metabolic and Cardiovascular Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 3, 2016

First Posted

October 5, 2016

Study Start

February 1, 2015

Primary Completion

February 1, 2016

Study Completion

February 1, 2016

Last Updated

May 15, 2018

Record last verified: 2018-05

Data Sharing

IPD Sharing
Will not share